Your browser is unsupported

We recommend using the latest version of IE11, Edge, Chrome, Firefox or Safari.

Photo of Beck, William T

William T Beck

UIC Distinguished Professor Emeritus, Pharmaceutical Sciences

Related Sites:

Research Interests Heading link

Molecular and genetic mechanisms of anticancer drug action and tumor cell resistance to anticancer drugs; splicing factors in cancer initiation, tumor progression, and resistance to therapy, and their potential as novel therapeutic targets to treat ovarian and breast cancers; multidrug resistance; topoisomerases in anticancer drug sensitivity/resistance.

Teaching and Supervision Heading link

Pharmaceutical Applications of Genomics and Bioinformatics (MDCH/PMMP 412), 8/20/2018 – Present
PDAT 5: Cardiovascular (PHAR 505), 1/16/2018 – 5/4/2018

Selected Grants

College of Pharmacy Summer Undergraduate Research Fellowships, Amer Soc for Pharmacology & Experimnt Therapeutics, 1/1/2015 - 12/31/2021, Obligated Amount: $36000; Anticipated Amount: $36000

Grant U10 CA 27469 Committee Of Experimental Medicine, Gynecology Oncology Group., 4/1/2013 - 2/28/2014, Obligated Amount: $7621; Anticipated Amount: $7621

Grant #U10 CA 27469 Committee On Experimental Medicine, Gynecology Oncology Group., 4/1/2012 - 3/31/2013, Obligated Amount: $9125; Anticipated Amount: $9125

Technical Testing Agreement with The Univesity of Chicago, Institute for Genomics and Systems Biology, Cellular Screening Center, University of Chicago., 12/6/2011 - 2/28/2013, No Obligated Amount Set; No Anticipated Amount Set

Function of the MRP Family, Icahn School of Medicine at Mount Sinai., 9/12/2011 - 6/30/2012, Obligated Amount: $79500; Anticipated Amount: $79500

U10 CA27469 Committee On Experimental Medicine Committee, Gynecology Oncology Group., 4/1/2011 - 3/31/2012, Obligated Amount: $10285; Anticipated Amount: $10285

Grant # U10 CA27469 Committee on Experimental Medicine Committee, Gynecology Oncology Group., 4/1/2010 - 3/31/2011, Obligated Amount: $5500; Anticipated Amount: $5500

Function Of The MRP Family, National Institutes of Health (National Cancer Institute)., 7/1/2009 - 6/30/2011, Obligated Amount: $843509; Anticipated Amount: $843509

Splicing Factors As Therapeutic Targets For Treatment Of Ovarian Cancer, National Institutes of Health (National Cancer Institute)., 5/1/2009 - 12/31/2014, Obligated Amount: $1239543; Anticipated Amount: $1258464

Selected Publications

Ho, TT, He, X, Mo, YY, Beck, WT. (2016). Transient resistance to DNA damaging agents is associated with expression of microRNAs-135b and -196b in human leukemia cell lines. International Journal of Biochemistry and Molecular Biology7, (2), 27-47.

Gardeux, Vincent, Arslan, Ahmet D, Achour, Ikbel, Ho, Tsui-Ting, Beck, William T, Lussier, Yves A. (2014). Concordance of deregulated mechanisms unveiled in underpowered experiments: PTBP1 knockdown case study. BMC Medical Genomics7, (Suppl 1), s1. doi:10.1186/1755-8794-7-s1-s1.

He, X, Arslan, AD, Ho, T-T, Yuan, C, Stampfer, MR, Beck, WT. (2014). Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. Oncogenesis3, (1), e84-e84. doi:10.1038/oncsis.2013.47.

Xie, Yi, Natarajan, Karthika, Bauer, Kenneth S, Nakanishi, Takeo, Beck, William T, Moreci, Rebecca S, Jeyasuria, Pancharatnam, Hussain, Arif, Ross, Douglas D. (2013). Bcrp1 transcription in mouse testis is controlled by a promoter upstream of a novel first exon (E1U) regulated by steroidogenic factor-1. Biochimica et Biophysica Acta (BBA) – Lipids and Lipid Metabolism1829, (12), 1288-1299. doi:10.1016/j.bbagrm.2013.10.008.

Arslan, Ahmet Dirim, He, Xiaolong, Wang, Minxiu, Rumschlag-Booms, Emily, Rong, Lijun, Beck, William T. (2012). A High-Throughput Assay to Identify Small-Molecule Modulators of Alternative Pre-mRNA Splicing. SLAS DISCOVERY18, (2), 180-190. doi:10.1177/1087057112459901.

He, X, Arslan, AD, Pool, MD, Ho, T-T, Darcy, KM, Coon, JS, Beck, WT. (2010). Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene30, (3), 356-365. doi:10.1038/onc.2010.426.

Shen, Fei, Bailey, Barbara J, Chu, Shaoyou, Bence, Aimee K, Xue, Xinjian, Erickson, Priscilla, Safa, Ahmad R, Beck, William T, Erickson, Leonard C. (2009). Dynamic Assessment of Mitoxantrone Resistance and Modulation of Multidrug Resistance by Valspodar (PSC833) in Multidrug Resistance Human Cancer Cells. Journal of Pharmacology and Experimental Therapeutics330, (2), 423-429. doi:10.1124/jpet.109.153551.

Wu, Fangting, Zhu, Shuomin, Ding, Yanna, Beck, William T, Mo, Yin-Yuan. (2009). MicroRNA-mediated Regulation of Ubc9 Expression in Cancer Cells. Clinical Cancer Research15, (5), 1550-1557. doi:10.1158/1078-0432.ccr-08-0820.

Shen, Fei, Chu, Shaoyou, Bence, Aimee K, Bailey, Barbara, Xue, Xinjian, Erickson, Priscilla A, Montrose, Marshall H, Beck, William T, Erickson, Leonard C. (2007). Quantitation of Doxorubicin Uptake, Efflux, and Modulation of Multidrug Resistance (MDR) in MDR Human Cancer Cells. Journal of Pharmacology and Experimental Therapeutics324, (1), 95-102. doi:10.1124/jpet.107.127704.

Education

Degrees:
PhD, George Washington University, United States